

## Pier Francesco Ferrucci, MD

### Personal Data:

Name: Pier Francesco Ferrucci  
Date of birth: October, 04, 1964  
Place of birth: Livorno, Italia  
Status: Married with one son.  
Present employment: Director, Oncology of Melanoma Unit, IEO Milano, Italy.  
Telephones: Work: 02-94371094      02-57489459.  
e-mail: pier.ferrucci@ieo.it

### General Data:

1984 Author of the world famous joke known as "the fake heads of Modigliani".

### Education and PhD/Masters/Courses

July 1983 "Diploma di Maturità classica sperimentale", score 55/60.  
31 October 1990 Medical doctor, University of Pisa, score 110/110.  
8 November 1994 Specialization in Medical Oncology, University of Perugia, magna cum laude.  
1997-2007 Haematology expertise at European Institute of Oncology  
21 October 2001 "European Certification on Medical Oncology" at European Society for Medical  
Oncology in Lisbona score 56/60.  
2011 – 2012 Certification "Management in Health Care Course" for Department Directors.

### Titles (included other positions covered)

1992-present Membership of the Nord-Ovest Oncology Group (GONO).  
1994-2003 Membership of the Italian Society of Internal Medicine.  
1994-present Membership of the Italian Society of Experimental Hematology.  
1995-present Membership of the American Association for Cancer Research.  
2000-present Membership of the European Society of Medical Oncology.  
1996-present Continuing Medical Education programme at the European Institute of Oncology.  
2000-present Reviewer for many internationally renowned journals  
2004-present: **Founder and Scientific Director of Foundation "Grazia Focacci" Onlus for Cancer Research.**  
2007-present: Membership NIBIT (Italian Network for Biotherapy of Tumors)  
2007-present: Membership IMI (Italian Melanoma Intergroup).  
2007-present: Member Editorial board Journal "Clinical Medicine Reviews: Oncology"  
2008-present: Member Editorial board of "eCancer medical science Journal"  
2008-present: Member EORTC Melanoma Group.  
2009-present: Member Editorial board of "The Open Biomarkers Journal"  
2013-present: Board of NIBIT (Italian Network for Biotherapy of Tumors)

### Clinical Activities carried out at IEO

Our clinical activity is focused on the treatment of melanoma, sarcoma and other cutaneous neoplasm using a comprehensive, multidisciplinary approach: patients are enrolled in clinical studies or receive state of the art drugs available as reported in national guide-lines. In particular we use immunomodulating agents (Ipilimumab, antiPD1, antiPDL1), vaccination drugs (NYESO), molecular target therapies (anti-BRAF, anti-CKIT, anti-NRAS) depending on the stage and extend of disease.

Every patient is discussed within a multidisciplinary group including surgeons, radiotherapists, radiologists, dermatologists, a psychologist and a molecular biologist in order to offer the best available options in a rationale sequence.

We have 30 dedicated ambulatory slots and 20 day hospital slots each week where treatments and controls are performed. The team is composed by 3 oncologists, 1 research nurse, 2 data manager, 1 biologist and 1 psychologist.

## Research Activities carried out at IEO

Our basic and translational research is done in cooperation with IEO Campus where a PhD biologist is working on projects with clinical impact, such as a study on Maspin predictive and prognostic role in melanoma progression, immunomonitoring during immunotherapy, angiogenesis during therapy with anti VEGF drugs and evaluation of circulating levels of HGF (Hepatocyte Growth Factor) during anti-BRAF therapy. Our aims are to identify new targets of possible therapies and new biomarkers to better follow results during treatments.

## Passed Clinical and Research Activities

1990	Medical training at the Charles University Medical Faculty, Hradec Kralovè, Cecoslovacchia.
1990-1994	Molecular Biology with Prof. P.G. Pelicci at the Institute of Internal Medicine and Oncologic Sciences, University of Perugia, Perugia, Italy.
1995-1996	Molecular Biology with Prof. P.G. Pelicci at IEO
1997-2007	Hæmatology expertise (HD CT with auto and allo-transplantation) at IEO

## Awards and other Recognitions

October 1992	Italian Prize for Research from the Italian Association of Internal Medicine.
October 1993	Italian Prize for Research from the Italian Association of Internal Medicine.
October 1994	Translational Research in Cancer Awardee, from the American Association for Cancer Research.
1995	“Margherita Florica Divora Award” by Italian Foundation for Cancer Research.
May 1999	“Hans Wider Award” by European School of Oncology Foundation.

## Publications

[Ipilimumab and fotemustine in patients with advanced melanoma \(NIBIT-M1\): an open-label, single-arm phase 2 trial.](#) Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini L, Simeone E, Nicoletti SV, Fonsatti E, Annesi D, Queirolo P, Testori A, Ridolfi R, Parmiani G, Maio M. *Lancet Oncol.* 2012 Sep;13(9):879-86.

[Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.](#) Del Vecchio M, Di Guardo L, Ascierto PA, Grimaldi AM, Sileni VC, Pigozzo J, Ferraresi V, Nuzzo C, Rinaldi G, Testori A, Ferrucci PF, Marchetti P, De Galitiis F, Queirolo P, Tornari E, Marconcini R, Calabrò L, Maio M. *Eur J Cancer.* 2014 Jan;50(1):121-7.

[Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy.](#) Chiarion-Sileni V, Pigozzo J, Ascierto PA, Simeone E, Maio M, Calabrò L, Marchetti P, De Galitiis F, Testori A, Ferrucci PF, Queirolo P, Spagnolo F, Quagliano P, Carnevale Schianca F, Mandalà M, Di Guardo L, Del Vecchio M. *Br J Cancer.* 2014 Mar 11.

[Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.](#) Altomonte M, Di Giacomo A, Queirolo P, Ascierto P, Spagnolo F, Bajetta E, Calabrò L, Danielli R, de Rosa F, Maur M, Chiarion-Sileni V, Ferrucci P, Giannarelli D, Testori A, Ridolfi R, Maio M. *J Exp Clin Cancer Res.* 2013 Oct 25;32(1):82.

[Sunny holidays before and after melanoma diagnosis are respectively associated with lower Breslow thickness and lower relapse rates in Italy.](#) Gandini S, De Vries E, Tosti G, Botteri E, Spadola G, Maisonneuve P, Martinoli C, Joosse A, Ferrucci PF, Baldini F, Cocorocchio E, Pennacchioli E, Cataldo F, Bazolli B, Clerici A, Barberis M, Bataille V, Testori A. *PLoS One.* 2013 Nov 4;8(11)

[Maspin expression and melanoma progression: a matter of sub-cellular localization.](#) Martinoli C, Gandini S, Luise C, Mazzarol G, Confalonieri S, Giuseppe Pelicci P, Testori A, Ferrucci PF. *Mod Pathol.* 2014 Mar;27(3):412-9.

[Newly identified tumor antigens as promising cancer vaccine targets for malignant melanoma treatment.](#) Ferrucci PF, Tosti G, di Pietro A, Passoni C, Pari C, Tedeschi I, Cataldo F, Martinoli C, Testori A. *Curr Top Med Chem.* 2012;12(1):11-31. Review.

[Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.](#) Danielli R, Ridolfi R, Chiarion-Sileni V, Queirolo P, Testori A, Plummer R, Boitano M, Calabrò L, Rossi CD, Giacomo AM, Ferrucci PF,

Ridolfi L, Altomonte M, Miracco C, Balestrazzi A, Maio M. *Cancer Immunol Immunother.* 2012 Jan;61(1):41-8.

[The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease.](#) di Pietro A, Tosti G, Ferrucci PF, Testori A. *Expert Opin Biol Ther.* 2011 Oct;11(10):1395-407.

[HSPPC-g6 vaccine in metastatic melanoma patients: from the state of the art to a possible future.](#) Tosti G, di Pietro A, Ferrucci PF, Testori A. *Expert Rev Vaccines.* 2009 Nov;8(11):1513-26.

[Oncophage: step to the future for vaccine therapy in melanoma.](#) di Pietro A, Tosti G, Ferrucci PF, Testori A. *Expert Opin Biol Ther.* 2008 Dec;8(12):1973-84. doi: 10.1517/14712590802517970 . Review.

[Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings.](#) Lens M, Ferrucci PF, Testori A. *Recent Pat Anticancer Drug Discov.* 2008 Jun;3(2):105-13. Review.

[Mammaglobin expression in leukapheresis products is a predictive marker of poor prognosis in women with high-risk breast cancer.](#) Ferrucci PF, Rabascio C, Mazzetta C, Cocorocchio E, Agazzi A, Vanazzi A, Cinieri S, Peccatori FA, Paolucci M, Bertolini F, Martinelli G. *Clin Cancer Res.* 2004 Sep 15;10(18 Pt 1):6039-46.

[Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma.](#) Bertolini F, Fusetti L, Mancuso P, Gobbi A, Corsini C, Ferrucci PF, Martinelli G, Pruneri G. *Blood.* 2000 Jul 1;96(1):282-7.

[Cooperation between the RING + B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survival.](#) Fagioli M, Alcalay M, Tomassoni L, Ferrucci PF, Mencarelli A, Riganelli D, Grignani F, Pozzan T, Nicoletti I, Grignani F, Pelicci PG. *Oncogene.* 1998 Jun 4;16(22):2905-13.

[Cell death induction by the acute promyelocytic leukemia-specific PML/RARalpha fusion protein.](#) Ferrucci PF, Grignani F, Pearson M, Fagioli M, Nicoletti I, Pelicci PG. *Proc Natl Acad Sci U S A.* 1997 Sep 30;94(20):10901-6.

[Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains.](#) Grignani F, Testa U, Rogaia D, Ferrucci PF, Samoggia P, Pinto A, Aldinucci D, Gelmetti V, Fagioli M, Alcalay M, Seeler J, Grignani F, Nicoletti I, Peschle C, Pelicci PG. *EMBO J.* 1996 Sep 16;15(18):4949-58.

[Characterization of a new monoclonal antibody \(PG-M3\) directed against the aminoterminal portion of the PML gene product: immunocytochemical evidence for high expression of PML proteins on activated macrophages, endothelial cells, and epithelia.](#) Flenghi L, Fagioli M, Tomassoni L, Pileri S, Gambacorta M, Pacini R, Grignani F, Casini T, Ferrucci PF, Martelli MF, et al. *Blood.* 1995 Apr 1;85(7):1871-80.

[PML/RAR alpha+ U937 mutant and NB4 cell lines: retinoic acid restores the monocytic differentiation response to vitamin D3.](#) Testa U, Grignani F, Barberi T, Fagioli M, Masciulli R, Ferrucci PF, Seripa D, Camagna A, Alcalay M, Pelicci PG, et al. *Cancer Res.* 1994 Aug 15;54(16):4508-15.

[The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells.](#) Grignani F, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Grignani F, Peschle C, Nicoletti I, et al. *Cell.* 1993 Aug 13;74(3):423-31.

## Congresses

More than 70 paper published in international "peer reviewed" journals.

More than 100 national and international congresses attended.

More than 100 abstract presented at national and international meetings.

More than 50 oral presentations done (ESMO, ASCO, AACR, EORTC, NIBIT, IMI).

More than 20 teaching/tutoring courses.